PIK3CA testing in HR+/HER2- metastatic breast cancer: assessing pathology laboratories capacity and needs.

Saved in:
Bibliographic Details
Title: PIK3CA testing in HR+/HER2- metastatic breast cancer: assessing pathology laboratories capacity and needs.
Authors: Mane E; Division of Pathology, European Institute of Oncology IRCCS, Milan, Italy., Cursano G; Division of Pathology, European Institute of Oncology IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Venetis K; Division of Pathology, European Institute of Oncology IRCCS, Milan, Italy., Frascarelli C; Division of Pathology, European Institute of Oncology IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Pepe F; Department of Public Health, Federico II University of Naples, Naples, Italy., Nacchio M; Department of Public Health, Federico II University of Naples, Naples, Italy., Palumbo L; Department of Public Health, Federico II University of Naples, Naples, Italy., Pisapia P; Department of Public Health, Federico II University of Naples, Naples, Italy., De Camilli E; Division of Pathology, European Institute of Oncology IRCCS, Milan, Italy., Castellano I; Unit of Pathology, Department of Medical Sciences, City of Health and Science University Hospital, University of Turin, Turin, Italy., Cerbelli B; Department of Medical-Surgical Sciences and Biotechnologies Sapienza University of Rome, Rome, Italy., Costarelli L; Unit of Pathology, San Giovanni-Addolorata Hospital, Rome, Italy., d'Amati G; Department of Medical-Surgical Sciences and Biotechnologies Sapienza University of Rome, Rome, Italy., Rizzo A; Division of Pathology, Clinical Institute Humanitas Catania, Misterbianco (CT), Italy., Santinelli A; Unit of Anatomic Pathology, Azienda Sanitaria Territoriale di Pesaro-Urbino, Pesaro, Italy., Scatena C; Division of Pathology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Criscitiello C; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan, Italy., De Angelis C; Clinical and Translational Oncology, Scuola Superiore Meridionale, Naples, Italy., Dieci MV; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.; Department of Oncology 2, Veneto Institute of Oncology IOV IRCCS, Padova, Italy., Troncone G; Department of Public Health, Federico II University of Naples, Naples, Italy., Curigliano G; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan, Italy., Viale G; Division of Pathology, European Institute of Oncology IRCCS, Milan, Italy., Guerini-Rocco E; Division of Pathology, European Institute of Oncology IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Malapelle U; Department of Public Health, Federico II University of Naples, Naples, Italy., Fusco N; Division of Pathology, European Institute of Oncology IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Corporate Authors: PIK3CA in breast cancer GIPaM/PMMP cooperative group
Source: Pathologica [Pathologica] 2025 Dec; Vol. 117 (6), pp. 571-579.
Publication Type: Journal Article
Journal Info: Publisher: Pacini Editore SpA Country of Publication: Italy NLM ID: 0401123 Publication Model: Print Cited Medium: Internet ISSN: 1591-951X (Electronic) Linking ISSN: 00312983 NLM ISO Abbreviation: Pathologica Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1591-951X
DOI:10.32074/1591-951X-1603